PubMed · 12876995
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Kyoko Kaji, Reiji Yoshimura, Jun Nakamura. 2003. [Double depression].. https://pubmed.ncbi.nlm.nih.gov/12876995/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Selective serotonin reuptake inhibitors (SSRIs) are widely used because of their safety, tolerability, and demonstrated efficacy across a broad range of clinical conditions. Medical literature supports the use of SSRIs for the treatment of many conditions outside of the indications approved by the U.S. Food and Drug Administration. SSRIs offer a reasonable alternative to traditional therapy for generalized anxiety disorder. A side effect of SSRIs coincidentally provides therapy for premature ejaculation. SSRIs may reduce the frequency and severity of migraine headaches and are possibly effective in reducing the pain of diabetic neuropathy. When taken in combination with tricyclic antidepressants, SSRis offer more potent therapy for fibromyalgia than either agent alone. SSRIs appear to be effective in some patients with neurocardiogenic syncope that is refractory to standard therapies. Clinical experience supported by ongoing research continues to expand on the broad array of therapeutic applications for this class of medication.
The effects of fluoxetine (Prozac) on the activity of human small-conductance calcium-activated potassium (SK) channels were investigated utilizing a functional fluorescence assay with bis-(1,3-dibutylbarbituric acid)trimethine oxonol (DiBAC(4)(3)). Fluoxetine blocked SK channels stably expressed in HEK 293 cells in a concentration-dependent manner displaying half-maximal inhibitory concentrations (IC(50)) of 9 microM for hSK1, 7 microM for hSK2 and 20 microM for hSK3. The block of hSK3 channels was confirmed by whole cell patch-clamp recordings of the recombinant cells and human TE 671 cells. Fluoxetine also inhibited [(125)I]apamin binding in a concentration-dependent manner displaying IC(50) values of 63 microM for hSK1, 148 microM for hSK2 and 295 microM for hSK3. These results provide new information concerning the mechanism of therapeutic and/or side effects of one of the most widely used antidepressant drugs.
Tobacco use represents the single most important preventable health hazard world-wide. Its consumption confers substantially increased mortality and morbidity due to cardiovascular, cerebrovascular and respiratory disease, and malignancy in a number of sites. A key goal towards improving public health in developing and developed countries alike is to reduce tobacco use across populations. Despite this, current data suggest that global tobacco use is increasing. There have been recent pharmacological advances that offer the hope of achieving more effective tobacco cessation and reduced consumption among established tobacco users. These are discussed in further detail, with reference to evidence supporting their use in clinical practice.